Yes – 340B ESP
Yes (CEs can designate 2 CPs – one for Xeljanz specifically and a specialty pharmacy for other oral oncology products affected by this policy
Xeljanz, Bosulfi, Braftovi,Daurismo, Ibrance, Inlyta, Lorbrena, Mektovi, Sutent, Talzenna and Xalkori
Policy applies to hospitals covered entities only. Federal grantees are exempted from this policy.